What microfracture was — and how it reached the hip

Microfracture earned its place in orthopaedic surgery honestly. Developed by Dr J. Richard Steadman from the 1980s, it offered something genuinely useful for damaged joint cartilage at a time when surgeons had few alternatives: a small awl is used to punch rows of tiny holes through the subchondral bone — the dense layer just beneath cartilage — releasing bone-marrow cells that pool into a 'super-clot' and gradually differentiate into repair tissue. The concept was straightforward, the equipment simple, and the procedure could be completed in a single arthroscopic session.

Credibility arrived early. Steadman's own group published eleven-year follow-up data in Arthroscopy in 2003, reporting durable outcomes in patients with traumatic chondral defects of the knee. That evidence made microfracture the default first-line cartilage repair procedure through the 1990s and into the following decade.

The route into hip surgery followed naturally from the boom in hip arthroscopy during the 2000s. As surgeons grew more confident treating femoroacetabular impingement (FAI) — a condition in which abnormal bone morphology damages the acetabular cartilage at the chondrolabral junction — they needed a cartilage repair tool they already knew. Microfracture, proven (in the knee), single-stage, and low-cost, was imported wholesale into hip practice. At the time, the anatomical and biological differences between the two joints received little scrutiny; the consequences of that assumption took years to become fully apparent.

Why the hip joint is a particularly demanding environment

The hip joint imposes structural demands that expose any fibrocartilage repair technique to failure more quickly and more completely than in other weight-bearing joints — and understanding those demands helps explain why microfracture's limitations became so apparent once it was applied there.

The acetabular cartilage lining the socket is notably thin, measuring approximately 1–2 mm in most adults. A perforation-based technique depends on having enough cartilage depth for repair tissue to integrate at the margins of a defect; in the hip, that buffer is minimal. The joint's deep spherical geometry adds a further practical constraint: arthroscopic access to the acetabular surface is technically demanding, making precise defect preparation — cleaning the lesion margins, stabilising the initial clot — harder to achieve than on the flatter femoral condyle of the knee where microfracture was developed and refined.

The position of FAI-related chondral lesions compounds both problems. Cartilage damage associated with cam or pincer impingement typically occurs at the chondrolabral junction — the rim where cartilage meets the labrum — producing defects that are often large, irregular, or partially uncontained. Published evidence identifies large, uncontained lesions as among the strongest predictors of microfracture failure; the hip's characteristic lesion profile sits squarely in that high-risk category.

High joint congruence means the femoral head and acetabulum fit closely together, concentrating axial load across a relatively small contact area. Repair tissue forming within that environment is subject to considerable cyclical stress with every step. These are structural constraints of the hip's anatomy — not avoidable surgical errors — and they mean the joint simply penalises an inferior repair material more severely, and sooner, than comparator joints do.

How microfracture repair tissue fails over time

The repair tissue microfracture produces is biologically distinct from the cartilage it replaces. Native articular cartilage is hyaline cartilage — built from type II collagen arranged in a layered zonal structure that gives it compressive stiffness and durability under load. Microfracture generates fibrocartilage instead: type I collagen, without that zonal architecture, and considerably less capable of withstanding the cyclical forces passing through a weight-bearing hip joint.

In the short term, this distinction is often invisible to patients. Pain typically improves as the repair tissue forms and stabilises, and functional gains in the first year or two can be meaningful. Beyond two to five years, however, fibrocartilage tends to fissure and thin progressively under physiological load — a pattern well documented in the published literature. As the repair tissue degrades, symptoms return.

The more consequential problem, seen in failures, is what happens to the bone beneath. Subchondral bone damage — including cyst formation and intralesional osteophyte development — has been reported in approximately 93% of microfracture failures in one series. Within the acetabulum or on the femoral head, these osseous changes are particularly significant: they undermine the structural foundation a subsequent repair procedure requires and may complicate any future hip surgery, including arthroplasty.

This failure mode is qualitatively different from simple symptom recurrence. Patients who develop subchondral changes after microfracture may find that more advanced cartilage repair options become technically harder or no longer possible — narrowing the treatment pathway before it has been fully explored.

When the evidence turned — and use declined

Practice did not wait for a definitive hip-specific randomised trial. By 2015, trends data published by Westermann and colleagues in Orthopaedic Journal of Sports Medicine documented a measurable fall in microfracture use for articular cartilage repair as surgeons moved toward techniques producing higher-quality tissue — a shift driven by mechanistic understanding and observed mid-term outcome patterns rather than by head-to-head trial results.

That evidential picture carries an important qualification. The bulk of quantitative outcome data for microfracture comes from the knee, where the technique was developed and most thoroughly studied. Hip-specific long-term series are sparser, and the field moved on before large randomised trials in the hip were completed. Surgeons acted because the failure modes were biologically predictable and clinically consistent — progressive fibrocartilage degradation, subchondral bone damage, return of symptoms — and because alternatives existed. The evidence hierarchy for hip cartilage repair as a whole remains lower than for hip arthroplasty; this particular change in practice was a response to converging mechanistic and mid-term signals rather than a single landmark trial.

Microfracture has not disappeared. It remains available at some centres, particularly where access to newer techniques is limited or where a small, contained focal defect — typically graded ICRS III or below — falls within the size range for which marrow stimulation was historically considered appropriate. It is no longer regarded as a first-line option for hip chondral defects where a broader range of cartilage repair pathways can be offered.

Understanding what replaced it requires looking at what the hip environment actually demands from a repair material.

What replaced microfracture in hip cartilage repair

The techniques that followed microfracture each addressed a different part of its failure mechanism.

AMIC (autologous matrix-induced chondrogenesis) was the most direct evolution: a resorbable collagen membrane is secured over the microfracture defect, improving clot retention and guiding more organised repair tissue than marrow stimulation alone. It remains single-stage and has accumulated more than a decade of trial evidence comparing it favourably with microfracture alone.

ACI and MACI take a more ambitious step. Autologous chondrocyte implantation harvests the patient's own cartilage cells, expands them in laboratory culture, and re-implants them to produce hyaline-like tissue rather than fibrocartilage. MACI seeds those cells onto a type I/III collagen membrane, reducing some of the first generation's technical demands. The cost is two surgical stages and resource-intensive cell processing; hip-specific outcome data, while available, is considerably more limited than the established knee literature.

Osteochondral procedures — OATS (mosaicplasty, using the patient's own bone-cartilage plugs) and OCA (osteochondral allograft, using donor tissue) — transfer intact cartilage-bone units rather than regenerating tissue in situ. Both offer durable structural repair for focal defects; with autograft, donor-site morbidity from the harvest area is a meaningful clinical consideration.

BMAC (bone marrow aspirate concentrate) provides a richer environment of mesenchymal stem cells and growth factors than standard microfracture, delivered in a single session. In hip cartilage care it functions as a biologic adjunct rather than a standalone restorative technique.

NanoACi, developed by Professor Paul Lee at the London Cartilage Clinic, is the most recent addition: a non-arthroscopic, needle-delivered, single-session procedure combining autologous cartilage micrografts, an acellular type I collagen scaffold, and autologous platelet-rich fibrin. Each component carries its own established evidence base; combined-protocol outcomes are still being collected prospectively through the NanoACi 100 programme — making this the least evidentially mature option listed here, despite the novelty of its non-arthroscopic design.

A gap persists across all these techniques: none is well suited to diffuse cartilage loss. Patients whose damage is too widespread for focal repair yet who are not ready for hip replacement remain the hardest group to help along any preservation pathway.

What this means for hip patients today

For a patient with hip cartilage damage, the practical implication of this history resolves into a single shift in framing: the question is no longer "can I have microfracture?" but "has my lesion been characterised accurately enough to match the right repair to it?"

That characterisation — grade, size, location, and whether the defect is contained — drives every subsequent choice. A small, contained lesion at ICRS grade III may suit a scaffold-based approach; a larger focal defect in a younger patient may point toward a cell-based technique or a newer injectable route. Diffuse damage changes the conversation from restoration to preservation.

Patients who have already had microfracture face an additional layer of assessment. Subchondral bone changes — marrow oedema, cyst formation, and intralesional osteophyte formation — can limit which subsequent procedures remain technically viable. The state of the subchondral plate matters as much as the cartilage surface above it before any further intervention is planned.

Across all the techniques that have followed microfracture, long-term hip-specific comparative data remains limited. Patients should enter any cartilage preservation pathway with realistic expectations rather than timelines drawn from the richer knee literature.

A specialist assessment in a hip cartilage-preservation setting — as distinct from a general orthopaedic review — gives patients the lesion mapping, surgical history review, and honest pathway discussion these decisions require. For younger patients especially, timing is not neutral: the subchondral bone beneath a focal defect narrows future repair options faster than the cartilage surface above it suggests.

1. [1] Microfracture surgery. https://en.wikipedia.org/?curid=8840994 https://en.wikipedia.org/?curid=8840994
2. [2] Richard Steadman. https://en.wikipedia.org/?curid=5717817 https://en.wikipedia.org/?curid=5717817
3. [3] Hyaline cartilage. https://en.wikipedia.org/?curid=1130627 https://en.wikipedia.org/?curid=1130627
4. [4] Articular cartilage repair. https://en.wikipedia.org/?curid=19042351 https://en.wikipedia.org/?curid=19042351